New Delhi: Blood clot syndrome from the Oxford/AstraZeneca vaccine is extremely rare, can be very serious and carries a high risk of death, which can occur in other healthy and young individuals, a new study has shown.
According to a study published in New England Journal of Medicine, that the syndrome occurs in at least 1 in every 50,000 vaccinated people under the age of 50.
Read also: FDA ready to clear third shot of COVID-19 vaccine for people with weakened immune systems
Researchers examined patients suspected of vaccine-induced immune thrombocytopenia and thrombosis (VITT) who presented in UK hospitals between March 22, 2021 and June 6, 2021. Of the 294 patients who were evaluated, 170 had definite and 50 probable cases of VITT.
“All patients had received the first dose of ChAdOx1 nCoV-19 vaccine and presented 5 to 48 days after vaccination.”
“What we have learned in the UK is extremely important for other countries,” Dr Sue Pavord, a researcher at Oxford University Hospitals, told Bloomberg during a briefing. “If they can recognize the condition and manage it promptly, they can continue to vaccinate.”
The researcher also noted that about half of them had no prior health conditions and the rest did not have any particular individual risk factors for the syndrome. They found that people with low platelet counts and intracranial bleeding had the highest risk of blood clots.
He hopes the findings will help countries that rely heavily on the AstraZeneca vaccine to respond to the pandemic decide who should get the vaccine.
See below health equipment-
Calculate your body mass index (BMI)
.